FDA rejects Bayer/J&J's Xarelto, agai

24th February 2014

It certainly wasn’t third time lucky for drug giants Bayer and Johnson & Johnson after US regulators yet again refused to approve wider uses of their bloodthinner Xarelto (rivaroxaban).
The US Food and Drug Administration has issued a third rejection for the drug to reduce the risk of heart attack, stroke or death in patients with acute coronary syndrome (ACS).Read more at source: www.pharmatimes.com


Leave a Reply

Your email address will not be published.

3 + 7 =

« back to posts